San Diego, CA (December 14, 2005) — Eidogen-Sertanty, Inc., a San Diego-based computational drug discovery solutions provider, today announced that they have established a collaboration with San Diego-based Kalypsys, Inc, focused on the discovery of novel small molecules for anti-inflammatory indications.

Under the terms of the collaboration, Eidogen-Sertanty will utilize its DirectDesign™ computational drug discovery platform to design a virtual library of novel, synthetically tractable, and drug-like compounds with predicted activity against a target of interest to Kalypsys. The collaboration builds upon Kalypsys' existing relationship with Eidogen-Sertanty as a customer of the Target Informatics Platform™ (TIP™).

"The team at Eidogen-Sertanty believes that our expertise in targeted library design will help deliver leads for Kalypsys' small molecule pipeline," said Dr. Steve Muskal, CEO of Eidogen-Sertanty.

"We are pleased to partner with Eidogen-Sertanty. Their technology appears to have great potential and we look forward to applying it to this research effort," stated Stewart Noble, VP of Chemistry at Kalypsys.

About Kalypsys, Inc.

Kalypsys is a privately owned San Diego-based small molecule drug discovery and development company that is applying its integrated drug discovery infrastructure, suite of ultra-high throughput lead discovery technologies, and seasoned team of scientists to advance its pipeline into clinical development. Kalypsys uses its technologies, integrated capabilities, and sizeable drug-like compound collection to improve the drug discovery research process and generate a robust pipeline for itself and its partners. Kalypsys' mission is to participate in targeted commercial opportunities by building a sustainable drug candidate pipeline from target to proof of efficacy and safety in the clinic with unmatched speed, efficiency, and success rates. For more information on Kalypsys, please visit www.kalypsys.org.

About Eidogen-Sertanty, Inc.

Eidogen-Sertanty, formed in March 2005 from the merger of Eidogen and Sertanty, is a privately held company providing pioneering knowledge-driven discovery solutions to biotechnology and pharmaceutical organizations. Eidogen-Sertanty's unique and powerful suite of software, databases, and drug discovery services enable customers and collaborators to apply a knowledge-driven discovery approach to a variety of workflows and processes, including target selection and prioritization, library building and compound prioritization, and lead design and optimization. To find out more about Eidogen-Sertanty and their products and services please visit www.eidogen-sertanty.com.